Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette- Guérin;Segunda resección transuretral y pronóstico del cáncer de vejiga no músculo-invasivo de alto grado en pacientes que no reciben bacilo de Calmette-Guérin

Actas Urologicas Espanolas

Volumn 38, Issue 3, 2014, Pages 164-171

  Angulo, J C ^a   Palou, J ^b   Garcia Tello A ^a   De Fata, F R ^a   Rodriguez O ^b   Villavicencio, H ^b  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Bacillus Calmette Guerin; Prognosis; Second transurethral resection; T1G3

Indexed keywords

BCG VACCINE;

ADULT; AGED; CANCER GRADING; CARCINOMA, PAPILLARY; CARCINOMA, TRANSITIONAL CELL; COMPARATIVE STUDY; CYSTECTOMY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; REOPERATION; RETROSPECTIVE STUDY; RISK; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA, PAPILLARY; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REOPERATION; RETROSPECTIVE STUDIES; RISK; URINARY BLADDER NEOPLASMS;

EID: 84897371859     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2014.01.001     Document Type: Article

References (30)

1. B. Miñana, J.M. Cózar, J. Palou, M. Unda Urzaiz, R.A. Medina-Lopez, and J. Subirá Ríos et al. Bladder cancer in Spain 2011: A population based study J Urol 191 2014 323 328
2. F. Palmieri, E. Brunocilla, A. Bertaccini, M. Guidi, R. Pernetti, and A.M. Morselli-Labate et al. Prognostic value of lymphovascular invasion in bladder cancer in patients treated with radical cystectomy Anticancer Res 30 2010 2973 2976
3. N.M. Heney, S. Ahmed, M.J. Flanagan, W. Frable, M.P. Corder, and M.D. Hafermann et al. Superficial bladder cancer: progression and recurrence J Urol 130 1983 1083 1086
4. C. Anderström, S. Johansson, and S. Nilsson The significance of lamina propria invasion on the prognosis of patients with bladder tumors J Urol 124 1980 23 26
5. G.S. Kulkarni, O.W. Hakenberg, J.E. Gschwend, G. Thalmann, W. Kassouf, and A. Kamat et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer Eur Urol 57 2010 60 70
6. S. Van den Bosch, and A.J. Witjes Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: A systematic review Eur Urol 60 2011 493 500
7. R.J. Sylvester, A.P. van der Meijden, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
8. A. Páez Borda, M. Luján Galán, J.M. Gómez de Vicente, A. Moreno Santurino, F. Abate, and A. Berenguer Sánchez Preliminary results of the treatment of high grade (T1G3) superficial tumors of the bladder with transurethral resection Actas Urol Esp 25 2001 187 192
9. J.M. Fernández-Gómez, J. Carballido-Rodríguez, J.M. Cozar-Olmo, J. Palou-Redorta, E. Solsona-Narbón, and J.M. Unda-Urzaiz Treatment of non muscle invasive bladder tumor related to the problem of bacillus Calmette-Guerin availability. Consensus of a Spanish expert's panel Actas Urol Esp 37 2013 387 394
10. G.S. Kulkarni, A. Finelli, N.E. Fleshner, M.A. Jewett, S.R. Lopushinsky, and S.M. Alibhai Optimal management of high-risk T1G3 bladder cancer: A decision analysis PLoS Med 4 2007 e284
11. F. Millán-Rodríguez, G. Chéchile-Toniolo, J. Salvador-Bayarri, J. Palou, and J. Vicente-Rodríguez Multivariate analysis of the prognostic factors of primary superficial bladder cancer J Urol 163 2000 73 78
12. J. Palou Redorta, P. Schatteman, J. Huguet Pérez, J. Segarra Tomás, A. Rosales Bordes, and F. Algaba et al. Intravesical instillations with bacillus Calmette-Guérin for the treatment of carcinoma in situ involving prostatic ducts Eur Urol 49 2006 834 838
13. A. Orsola, L. Cecchini, C.X. Raventós, E. Trilla, J. Planas, and S. Landolfi et al. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR BJU Int 105 2010 202 207
14. S. Denzinger, M. Burger, H.M. Fritsche, S. Bertz, F. Hofstädter, and W.F. Wieland et al. Prognostic value of histopathologicaltumour growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder Scand J Urol Nephrol 43 2009 282 287
15. S. Denzinger, H.M. Fritsche, W. Otto, A. Blana, W.F. Wieland, and M. Burger Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: Do risk factors define feasibility of bladder-sparing approach? Eur Urol 53 2008 146 152
16. E. Solsona, I. Iborra, R. Dumont, J. Rubio-Briones, J. Casanova, and S. Almenar The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer J Urol 164 2000 685 689
17. J. Palou, R.J. Sylvester, O.R. Faba, R. Parada, J.A. Peña, and F. Algaba et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin Eur Urol 62 2012 118 125
18. J.A. Witjes Prognosis of T1G3 bladder cancer: How well can we predict progression? Eur Urol 62 2012 126 127
19. R. Persad, D. Lamm, M. Brausi, M. Soloway, and J. Palou Current approaches to the management of non-muscle invasive bladder cancer: Comparison of current guidelines and recommendations Eur Urol Suppl 7 2008 637 650
20. J. Fernandez-Gomez, R. Madero, E. Solsona, M. Unda, L. Martinez-Piñeiro, and A. Ojea et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: External validation of the EORTC risk tables Eur Urol 60 2011 423 430
21. E. Xylinas, M. Kent, L. Kluth, A. Pycha, E. Comploj, and R.S. Svatek et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder Br J Cancer 109 2013 1460 1466
22. R.J. Sylvester, M.A. Brausi, W.J. Kirkels, W. Hoeltl, F. Calais da Silva, and P.H. Powell et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30,911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder Eur Urol 57 2010 766 773
23. E.H. Lambert, P.M. Pierorazio, C.A. Olsson, M.C. Benson, J.M. McKiernan, and S. Poon The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy BJU Int 100 2007 33 36
24. J.M. Gaya, J. Palou, M. Cosentino, D. Patiño, O. Rodríguez-Faba, and H. Villavicencio A second transurethral resection could be not necessary in all high grade non-muscle-invasive bladder tumors Actas Urol Esp 36 2012 539 544
25. M. Brausi, L. Collette, K. Kurth, A.P. van der Meijden, W. Oosterlinck, and J.A. Witjes et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies Eur Urol 41 2002 523 531
26. S. Sivalingam, J.L. Probert, and H. Schwaibold The role of repeat transurethral resection in the management of high-risk superficial transitional cell bladder cancer BJU Int 96 2005 759 762
27. R.T. Divrik, A.F. Sahin, U. Yildirim, M. Altok, and F. Zorlu Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: A prospective randomised clinical trial Eur Urol 58 2010 185 190
28. R.T. Divrik, U. Yildirim, F. Zorlu, and H. Ozen The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: A prospective, randomized clinical trial J Urol 175 2006 1641 1644
29. G. Novara, and V. Ficarra Does routine second transurethral resection affect the long-term outcome of patients with T1 bladder cancer? Why a flawed randomized controlled trial cannot address the issue Eur Urol 58 2010 193 194
30. A.A. El-Abbady, M.S. Shoukry, A.G. Hanno, L.K. Younis, and M. Abdel-Rahman Repeated transurethral resection of recurrent superficial bladder tumors. Does it affect the spread and stage of the tumor? Scand J Urol Nephrol 36 2002 60 64